A Phase 1 interventional study of Cannabidiol (CBD) in Musculoskeletal Pain, sponsored by Pure Green. Completed at 1 site in United States. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2020-03-24.
Sponsored by Pure Green · Phase 1, Interventional, and Treatment
The purpose of the study is to evaluate whether Pure Green tablets is a better pain reliever for the treatment of mild to moderate musculoskeletal pain.
494 studies on the registry are indexed under Musculoskeletal Pain; 113 are open to participants now.
This study's enrollment of 16 is below the median of 68 across 347 interventional studies indexed under Musculoskeletal Pain.
Browse Musculoskeletal Pain studies →Pure Green is the lead sponsor of 6 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
A water-soluble sublingual tablet that contains 5 mg of cannabidiol (CBD).
Drug: Cannabidiol (CBD)
A single dose of Cannabidiol (CBD) when patients experience musculoskeletal pain in the trial.
Impact of Pure Cannabidiol (CBD) tablets on safety in patient's with musculoskeletal pain using a self-reported pain scale score.
To evaluate the safety and efficacy of Pure Green Cannabidiol (CBD) sublingual tablets for the treatment of musculoskeletal pain by having patients evaluate their Numeric Pain Rating Scale (NPRS) score reported as 0-10 where 0 is no pain and 10 is the worst pain possible.
Time frame: 1 Day
To evaluate efficacy of a low dose of Cannabidiol (CBD) in the treatment of mild to moderate musculoskeletal pain.
To explore the impact of Pure Green sublingual tablets on patient self-reported Numeric Pain Rating Scale (NPRS), as a route of administration and reduction in baseline pain scores.
Time frame: 1 Day
Plan to share: No
This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pure Green